20 articles
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
TONTT2 tests whether erythropoietin dose and timing can be optimized to best preserve vision after traumatic optic neuropathy.
Italian researchers developed a biosensor to track extracellular vesicles in blood, potentially personalizing stroke rehabilitation.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
Large 503-patient study tested whether Actovegin could improve thinking and memory problems that persist after stroke recovery.
A VA-sponsored trial tested whether the blood pressure drug prazosin could remove toxic proteins linked to CTE and Alzheimer's in combat veterans.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
A Phase 4 RCT tests whether one bevacizumab injection matches two combined doses for neovascular AMD outcomes over 12 months.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
Novel movement program combining Eastern and Western exercises may help maintain independence and cognitive function in dementia patients.
Mayo Clinic study reveals how early estrogen treatment affects brain blood flow and cognitive aging in postmenopausal women.
A Phase 1 trial of AV-1959R, an Aβ-targeting vaccine, tests safety and antibody generation in healthy adults aged 40–60.
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
60-person study tested psilocybin alone and with CBT for major depression, measuring brain activity and inflammatory markers.
A completed Phase 1 trial compared the abuse liability of rapastinel versus ketamine in recreational polydrug users, with implications for safer depression treatment.
Duke University study tests whether targeted brain stimulation can reverse age-related cognitive decline and improve working memory.
Small study tests psychedelic compound's safety and effectiveness against severe depression that doesn't respond to standard treatments.
Probucol, a discontinued cholesterol medication, may boost brain-protective proteins in older adults at risk for dementia.
The EPICURO trial tests MERIVA® turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
